Find Academic Supervisors

Divya TiwariView profile

Lecturer

• Tuberculosis
• Host-Pathogen Interaction
• Drug Discovery
• +2 more

Dr. Divya Tiwari serves as a Barts Charity Lecturer at the Centre for Immunobiology, Blizard Institute, Queen Mary University of London, where she leads research on tuberculosis pathogenesis and host-pathogen interactions in Mycobacterium tuberculosis. Her work focuses on identifying novel drug targets to enhance host immune responses against drug-resistant TB strains, addressing a critical global health challenge. Her academic journey includes a Bachelor of Science and Master of Science in Microbiology from Pt Ravishankar Shukla University, India, a PhD from the National Institute of Immunology, New Delhi, and postdoctoral training at Weill Cornell Medicine, New York. Prior to her current role, she contributed to research administration as a Grants Adviser for The Wellcome Trust DBT India Alliance. Dr. Tiwari's research program centers on tuberculosis mechanisms, particularly how Mtb manipulates host immunity and identifying metabolic pathways like biotinylation and respiratory chain plasticity for therapeutic intervention. Her work bridges fundamental molecular biology and translational drug development to combat persistent and drug-resistant infections. Analysis of her 12 publications (2007-2023) reveals a consistent trajectory in TB drug discovery, with recent emphasis on host-directed therapies (2023) and inflammation-mediated tissue damage, while earlier work established foundational insights into bacterial metabolism targets. This evolution demonstrates progression from molecular mechanisms to clinical applications. She established her independent research group through the Barts Charity Lectureship, leveraging prior grant advisory experience to secure research funding. Her work bridges the Centre for Immunobiology's focus on infectious disease immunity with global TB control efforts. Dr. Tiwari's laboratory operates within the Blizard Institute's Centre for Immunobiology, contributing to collaborative research on immune responses to intracellular pathogens and participating in Queen Mary's strategic initiatives in global health and antimicrobial resistance.

Frank SchroederView profile

Professor

• Chemical Biology
• Metabolomics
• Analytical Chemistry
• +3 more

Professor Frank Schroeder is a distinguished scientist at Cornell University and the Boyce Thompson Institute (BTI), holding appointments in both the Department of Chemistry and Chemical Biology and Biochemistry, Molecular and Cell Biology (BMCB) graduate fields. His research focuses on Chemical Biology and Cell Biology , particularly the structural and functional characterization of biogenic small molecules (BSMs) that regulate development, immunity, and inter-organism communication. He leads an interdisciplinary lab with active collaborations across Caltech, Weill Cornell, MIT, and Max Planck Institutes. Key Research Areas: Metabolomics of Caenorhabditis elegans and other nematodes Host-microbiota interactions in mammals Development of NMR/MS-based analytical methodologies Chemical ecology of fungi for antibiotic discovery Scientific Recognition: HHMI Faculty Scholars Program (2016) Daniel F. Klessig Distinguished Scientist title Teaching: Advanced Analytical Chemistry (CHEM6250) at Cornell Focus on NMR and mass spectrometry applications The lab's NMR-driven approaches have uncovered novel BSMs like gluconucleosides, acylspermidines, and ascaroside derivatives, revealing unexpected biosynthetic pathways and conserved functions across species. Recent work includes host-microbe co-metabolism in immune regulation and a groundbreaking click-chemistry enrichment strategy (DIMEN) for metabolome analysis. His team has trained numerous PhD students and postdoctoral researchers, many of whom now hold academic or industry positions.

Jo MorrisView profile

Professor

• Cancer Genetics
• DNA Repair
• Post-translational Modifications
• +5 more

Jo Morris is a Professor of Molecular Genetics at the University of Birmingham, UK. Her career spans roles including Reader in Cancer Genetics (2013–present), Senior Lecturer (2010–2013), and Fellowships at King’s College London (2007–2010, 2003–2006). She leads research at the intersection of cancer genetics, DNA repair, and post-translational modifications. Doctor of Philosophy, University of London (1999) Bachelor of Arts, University of York (1995) Research Focus: Morris's work explores how ubiquitin and SUMO pathways govern DNA damage responses, particularly in BRCA1-related breast and ovarian cancers. Her 2004 discovery of ubiquitin conjugation at double-strand breaks (108 citations) and subsequent studies on SUMO regulation of BRCA1 activity (Nature 2009) have shaped the field. Current projects include investigating SUMO activating enzymes and replication fork stability (grants from Cancer Research UK, Wellcome Trust, and Breast Cancer Campaign). Article Trends: Over 15 recent publications emphasize DNA repair mechanisms, synthetic lethality, and post-translational modifications. Key subfields include BRCA1/53BP1 interactions, SUMO/deubiquitinating enzymes (POH1, USP50), SENP7 chromatin regulation, and implications for cancer therapy. Scientific Awards: Breast Cancer Campaign Team of the Year 2009 Birmingham Founders Award 2017 SUMO in Double-Strand Break Repair Fellowship 2017 Grants & Collaborations: £1.4M Cancer Research UK grant (2015–2019) on ubiquitin in cancer £454.5K Breast Cancer Campaign Fellowship (2007–2011) Collaborations with Aga Gambus (MRC Fellow), CRUK Centre studentships, and international institutions (Queens University Belfast, University of Sydney).

• Enzyme Engineering
• Biocatalysis
• Protein Stability
• +4 more

Dr. Max Fürst is an Assistant Professor in the Biotechnology department at the Faculty of Science and Engineering, University of Groningen. His research focuses on enzyme engineering, biocatalysis, and protein stability with applications in pharmaceutical development and sustainable chemistry. With an active publication record extending to 2025, he maintains a strong research presence at the university. Dr. Fürst's research interests center on enzyme engineering and biocatalysis, particularly in the areas of monooxygenase research, nucleoside analog production, and lipopolysaccharide biosynthesis. His work bridges computational approaches with experimental validation to create novel biocatalysts for pharmaceutical and industrial applications. He has made significant contributions to understanding how non-proteinogenic components can be incorporated into enzyme design. His recent publications demonstrate a clear trajectory toward developing sophisticated biocatalytic systems with applications in antibiotic development, sustainable chemical production, and antibody engineering. The research shows increasing integration of computational methods with experimental biochemistry to solve complex problems in enzyme design and function. NWO Veni Grant (2021) Dr. Fürst has received competitive research funding including the prestigious NWO Veni Grant in 2021, which supported his early-career research. His work has attracted media attention, with coverage in both professional and popular outlets discussing his research on designer proteins and biocatalysis. His research contributes to UN Sustainable Development Goals, particularly in sustainable chemistry and health-related applications. His laboratory work focuses on enzyme engineering approaches, with particular emphasis on monooxygenases, nucleoside phosphorylases, and systems for lipopolysaccharide modification. The research group employs a combination of computational modeling, protein engineering, and whole-cell biocatalysis approaches to develop novel enzymatic systems with industrial and pharmaceutical applications.

Zhijun LiView profile

Professor

• Computational Chemistry
• Drug Design
• G-protein Coupled Receptors (GPCRs)
• +4 more

Zhijun Li, PhD , is a Professor in the Department of Chemistry and Biochemistry at Saint Joseph's University. His research integrates computational chemistry, bioinformatics, and AI-driven approaches to advance drug discovery and protein engineering, with a focus on G-protein coupled receptors (GPCRs) and allosteric modulation. Education: BS, Tsinghua University MS, Tsinghua University PhD, Vanderbilt University Research Interests: Dr. Li's work spans three core areas: (1) Allosteric regulation of GPCRs , particularly designing positive allosteric modulators for GLP-1R to treat diabetes and obesity; (2) AI-based protein design , leveraging cutting-edge tools to engineer proteins/antibodies for therapeutic targets like T-cell receptors; and (3) Computational molecular design , applying bioinformatics to solve biomedical challenges collaboratively. Publication Trends: His recent articles emphasize GPCR allosteric modulation, AI-driven drug discovery, and antiviral therapeutics, reflecting a trajectory toward translational applications in metabolic and infectious diseases. Scientific Awards & Grants: W.W. Smith Charitable Trust (PI): "Formyl peptide receptor 2 modulators for heart disease" ($114,777, 2023) NIH/NIAID R01 (Co-I): "Non-nucleoside reverse transcriptase inhibitors for HIV" (sub-award $299,192, 2021-2024) NIH/NIGMS R15 (PI): "Common allosteric GPCR binding sites" ($527,500, 2020-2023) Labs & Teams: Dr. Li directs the Li Lab , relocated to SC 113H at Saint Joseph's University, and collaborates with the West Center for Computational Chemistry and Drug Design , fostering interdisciplinary computational research.

Katalin KarikoView profile

Adjunct Professor

• mRNA therapeutics
• vaccine development
• RNA biology
• +3 more

Katalin Kariko is a Hungarian-American biochemist and Adjunct Professor of Neurosurgery at the University of Pennsylvania's Perelman School of Medicine, holding a part-time academic position while serving as Senior Vice President at BioNTech. Her career spans over three decades of pioneering mRNA research. Her research focuses on mRNA therapeutics, vaccine development, and RNA biology with emphasis on nucleoside modifications to overcome immunogenicity barriers. Kariko's foundational work enabled the creation of mRNA vaccine platforms that achieved global impact during the COVID-19 pandemic through rapid development and deployment. Major scientific recognitions include: Nobel Prize in Physiology or Medicine (2023) Breakthrough Prize in Life Sciences (2021) Lasker-DeBakey Clinical Medical Research Award (2021) Cameron Prize for Therapeutics of the University of Edinburgh (2021) Kariko's career exemplifies perseverance in basic science, having advanced mRNA technology through decades of skepticism and funding challenges before its transformative medical applications. Her work continues to drive next-generation vaccine and therapeutic development at BioNTech while maintaining academic collaboration through her UPenn affiliation.

Clare Louise HawkinsView profile

Professor

• Atherosclerosis
• Oxidative stress
• Inflammation
• +11 more

Clare Louise Hawkins is a Professor in the Department of Biomedical Sciences within the Faculty of Health and Medical Sciences at the University of Copenhagen. She joined the department in March 2017 after nearly 20 years at the Heart Research Institute in Sydney, where she served as Scientific Director and Inflammation Group Leader. Her research focuses on understanding the role of oxidative stress and inflammation in driving lesion development in atherosclerosis and related chronic inflammatory diseases. BSc(Hons) Chemistry, University of York, UK (1993) PhD Chemistry, University of York, UK (1997) Professor Hawkins' research investigates how oxidants produced during inflammation modify biological molecules and cells associated with the arterial wall, with particular focus on immune cell extracellular traps and myeloperoxidase-derived oxidants. Her work spans multiple disciplines including redox biology, cardiovascular disease, diabetes complications, and innate immunity. The Hawkins Group employs in vitro immune and vascular cell models, biochemical and cellular assays, molecular biology techniques, and analytical methodologies including HPLC and EPR spectroscopy to study these complex interactions. Her recent publications reveal consistent themes across redox biology, inflammation, and vascular disease, with particular emphasis on hypohalous acids, histone modifications, extracellular traps, and nucleic acid oxidation. These studies collectively aim to develop targeted therapies that limit damaging reactions during chronic inflammation without compromising innate immune defenses. 2018: Lifetime Achievement Award and Lecture, Society for Free Radical Research (Australasia) 2018: Leopold Flohe Redox Pioneer Award and Lecture, Society for Free Radical Research (Europe) 2016: Blackmore's Mentor of the Year Award, HRI 2013-16: Australian Research Council Future Fellowship 2009-12: Career Development Fellowship, National Heart Foundation, Australia 2003-8: R. Douglas Wright Biomedical Fellowship, National Health and Medical Research Council, Australia Professor Hawkins has mentored more than 30 PhD students to completion and serves as a mentor for postdocs and assistant professors both at UCPH and internationally. Her research is supported by significant grants including funding from the Independent Research Fund Denmark, Royal Society of Chemistry, and Novo Nordisk Foundation. As Secretary-General of the Society for Free Radical Research (Europe) since 2021, she maintains extensive international collaborations across multiple continents. The Hawkins Group (Redox Biology Group) focuses on gaining detailed understanding of how inflammatory oxidants and extracellular traps contribute to disease development. The team actively investigates four main research projects: protective mechanisms of selenocyanate in inflammatory disease, post-translational histone modification in inflammation, macrophage extracellular traps in disease, and nucleic acid modification in diabetes and inflammatory disease.

Changchun ChenView profile

Associate Professor

• Molecular Biology
• Neuroscience
• Genetics
• +5 more

Changchun Chen is an Associate Professor at the Department of Molecular Biology, Umeå University, affiliated with the Wallenberg Centre for Molecular Medicine (UCMM). His research focuses on oxygen sensation mechanisms in Caenorhabditis elegans , combining genetic screens, biochemistry, calcium imaging, and optogenetics to unravel molecular and neural circuit adaptations to extreme conditions. Wallenberg Molecular Medicine Fellow (2018) ERC Starting Grant recipient (2018) Florman Prize from the Royal Swedish Academy of Sciences (2025) Chen’s work explores the neuronal basis of behavioral and physiological responses to hypoxia/anoxia, with implications for human pathogenesis. His lab investigates how ROS, cGMP, and IL-17 signaling modulate stress tolerance and survival strategies. Recent publications highlight his contributions to understanding GPCR signaling, tRNA modifications, and IL-17’s role in longevity. His studies often utilize C. elegans as a model for neurobiological and molecular disease mechanisms. ERC Starting Grant (€1.5 million) for molecular medicine research Florman Prize (2025) for breakthroughs in molecular biology The Changchun Chen Lab is part of Umeå University’s Department of Molecular Biology and collaborates with the Wallenberg Centre for Molecular Medicine. Funding sources include the Knut and Alice Wallenberg Foundation, European Research Council, and Swedish Research Council.

• Organic Chemistry
• Medicinal Chemistry
• Synthetic Methodology
• +4 more

Mauro Adamo is a Professor in the Department of Chemistry at the Royal College of Surgeons in Ireland (RCSI), with expertise in synthetic organic and medicinal chemistry. He has held progressive academic positions at RCSI since 2002, including Lecturer (2002–2007), Senior Lecturer (2007–2010), and Professor (2010–present). He obtained his PhD from the University of Sheffield (2001) and a Doctoral Degree from the University of Florence (1997). His research focuses on developing synthetic methodologies for drug discovery and production, with emphasis on enantioselective fluorination (including 18 F labeling), phase transfer catalysis, and hypervalent sulfur chemistry. He leads the MFAA research group, which has published over 60 papers and secured 5 patents. Key research areas include: Design of novel organocatalysts for asymmetric synthesis Continuous flow processes for pharmaceutical manufacturing Radiolabeled compounds for medical imaging Sustainable synthesis of HIV therapeutics Adamo's recent publications show interdisciplinary collaboration, with chemical research ( e.g. , desulfurative reactions, nucleoside synthesis) complemented by clinical co-authored works in neurosurgery. Chemistry articles emphasize green synthesis and catalytic innovation, while neurosurgery contributions focus on pediatric conditions and trauma management. He has led 51 funded projects, including major grants from Science Foundation Ireland, Enterprise Ireland, and Horizon 2020. Notable projects: Novel Therapeutics Targeting FcgRIIa receptor (2024–2026) Preparation of 18 F-labeled RNAs (2022–2023) Enantioselective fluorination for agrochemical/drug labeling (2018–2021) Flow chemistry processes for Paricalcitol synthesis (2018–2021) Professional memberships include the American Chemical Society and Royal Society of Chemistry. He has supervised multiple PhD/MSc students in organic synthesis and medicinal chemistry.

• Theoretical Biophysical Chemistry
• Computational Drug Discovery
• Molecular Modeling
• +4 more

Professor Leif Eriksson is a leading computational chemist in the Department of Chemistry and Molecular Biology at the University of Gothenburg, holding his professorship since 2011 after positions at NUI Galway and Dalhousie University. His research group comprises 1 research engineer, 2 postdocs, 1 doctoral student, and multiple Master's researchers focusing on AI-driven drug discovery. His educational background includes: Chemistry studies at Stockholm University and University of Sussex PhD in Quantum Chemistry, Uppsala University (1992) Postdoctoral Fellowship at Dalhousie University, Canada (1992-93) Research centers on theoretical biophysical chemistry with emphasis on computational modeling of DNA damage, cancer mechanisms, and antibiotic development. The group pioneers AI-based tools (MolAI, iScore) for ultrafast drug discovery, studying stress response pathways in glioblastoma/TNBC and developing inhibitors through multi-scale simulations from QM/MM to molecular dynamics. Recent work targets protein-protein interactions, membrane diffusion, and drug-loaded liposomes using integrated computational-experimental approaches. Publication trends (2022-2025) reveal strong focus on cancer therapeutics (35%), antibiotic discovery (25%), and AI-driven drug design (40%), with increasing integration of machine learning for ADMET prediction and target validation. Key journals include Journal of Chemical Information and Modeling (30%), Biochemistry (20%), and Scientific Reports (15%). Scientific recognition includes: Göta Student Union's Pedagogical Prize (2017) 300+ scientific papers and 20+ review chapters Patents for skin cancer/glioblastoma drugs leading to spin-offs (ANYO Labs, C26 Bioscience, Cell Stress Discoveries) Advising involves direct supervision of doctoral/postgraduate researchers with strong industry-academia pipelines. Grant funding is sustained through: National: Swedish Research Council, Swedish Cancer Society, Lawski Foundation International: Wenner-Gren Foundations, GBM Foundation, EU H2020 MSCA-RISE The lab maintains active collaborations with UGOT CARe for antibiotic resistance research and international networks for cancer drug validation. Research infrastructure leverages national supercomputing resources (via NAC leadership) and integrates wet-lab validation through spin-off partnerships. Current projects focus on translating computational discoveries into patentable therapeutics for aggressive cancers and antimicrobial resistance, with multiple compounds in preclinical development phases.

Albert Nguyen Van NhienView profile

Professor

• Ionic liquids
• Biomass pretreatment
• Chitin and chitosan
• +5 more

Professor Albert Nguyen Van Nhien is a faculty member at the University of Picardie Jules Verne, where he conducts research at the Glycochemistry and Agroresources Laboratory of Amiens (UR 7378 LG2A). His work bridges chemistry, materials science, and sustainable development, with a particular focus on bio-based solvents and biopolymers. His research interests include: Development and application of ionic liquids (particularly bio-based) and Deep Eutectic Solvents Chitin and chitosan chemistry and nanotechnology Biomass pretreatment and valorization Energy storage applications (batteries and solar cells) Sustainable materials for agricultural and biomedical applications Professor Nguyen Van Nhien's publication record demonstrates consistent high-impact research, with recent work focusing on chitin nanocrystal applications in agriculture, advanced electrolytes for energy storage, and sustainable biorefinery processes. His publications span top journals in chemistry, materials science, and green technology, showing a clear progression toward increasingly sophisticated applications of his core research areas. Notable research achievements include: Development of active coatings using oxidized chitin nanocrystals for controlling fungal diseases in fruits Creation of novel hybrid electrolytes for solid-state lithium-ion batteries Advancement of biobased-zwitterionic ionic liquids with improved biocompatibility Optimization of chitin extraction from insect sources for sustainable biorefineries Professor Nguyen Van Nhien actively collaborates with researchers across multiple disciplines, working on projects that address sustainability challenges in energy, agriculture, and materials science. His laboratory serves as a hub for innovative research at the intersection of chemistry, biology, and engineering, with a strong commitment to developing environmentally friendly technologies that translate fundamental scientific insights into practical solutions.

Vincent ChagnaultView profile

Associate Professor

• Glycochemistry
• Carbohydrate Chemistry
• Heparan Sulfate Analogues
• +4 more

Vincent Chagnault serves as an Associate Professor ( Maître de conférences ) at the University of Picardy Jules Verne within the Faculty of Science, Department of Chemistry. He conducts research at the Laboratoire de Glycochimie et des Agroressources d'Amiens (LG2A UR 7378), where he leads projects focused on carbohydrate-based therapeutic and sustainable material development. His research centers on heparan sulfate (HS) analogues , with three primary thrusts: 1) Synthesis of thiodisaccharide mimetics with enhanced stability for studying HS-protein interactions in inflammation and tumor growth; 2) Development of regioselective modification methodologies for carbohydrates using catalytic CoCl₂ and metal-free iodine-based reactions; 3) Creation of sustainable sugar-based surfactants with low cytotoxicity for potential replacement of petroleum-derived compounds. His work bridges synthetic organic chemistry with biological evaluation, yielding compounds with demonstrated activity against heparanase (IC50 in micromolar range) and selective antibacterial effects against Gram-positive pathogens. Analysis of his 15 most recent publications reveals consistent output in high-impact chemistry journals, with increasing interdisciplinary focus since 2020. His research demonstrates strong methodological innovation in carbohydrate chemistry while maintaining clear therapeutic and sustainability applications. The inclusion of French-language podcast explanations for several publications indicates active science communication efforts. Chagnault's work receives support through institutional funding at LG2A, with collaborative projects involving multiple French research entities. His laboratory maintains strong connections between synthetic chemistry development and biological validation, particularly through partnerships with groups specializing in enzyme kinetics and cellular assays. His laboratory focuses on glycochemical innovation , operating at the intersection of organic synthesis and biological application. The LG2A facility enables comprehensive carbohydrate modification, structural analysis, and preliminary biological screening. Current projects emphasize translating synthetic advances into practical applications for therapeutic development and sustainable materials.

Solen JosseView profile

Lecturer

• Organic Chemistry
• Glycochemistry
• Medicinal Chemistry
• +3 more

Solen Josse serves as a Lecturer at the University of Picardie Jules Verne, affiliated with the Glycochemistry and Agroresources Laboratory (UR 7378) in Amiens, France. Her research operates under the "Chemistry for the Living" axis, focusing on the synthesis of bioactive compounds at the chemistry-biology interface. Dr. Josse's research program centers on glycochemistry-driven drug discovery , with three interconnected pillars: (1) Developing TSAO-family nucleoside derivatives as antiviral agents against HIV and HCV; (2) Engineering cyanohydrin/aminocyanide intermediates for stereoselective spiroheterocyclic sugar synthesis; (3) Creating antiproliferative nucleoside analogs with isothiazole/oxathiole modifications for cancer therapy. Her work uniquely bridges carbohydrate chemistry with medicinal applications through innovative synthetic methodologies. Analysis of her 2014-2019 publications reveals consistent output in high-impact venues, demonstrating expertise in nucleoside analog design and green synthetic chemistry . Key trends include strategic phosphorus substitutions in antiviral compounds, metal-free carbohydrate modifications, and kinetic control in acetal formation – all contributing to sustainable drug development pipelines. Her research shows strong translational potential with a patent for antitumor agents. As part of the Glycochemistry and Agroresources Laboratory, Dr. Josse contributes to a collaborative ecosystem focused on sustainable chemistry and agroresource valorization. The lab provides comprehensive infrastructure for organic synthesis, biological testing, and structural analysis, supporting both fundamental research and applied therapeutic development projects within the University of Picardie's scientific framework.

Mark BrönstrupView profile

Professor

• Antibacterial Agents
• Antiviral Agents
• Antibiotic Discovery
• +5 more

Prof. Dr. Mark Brönstrup serves as Partner Site Speaker for the Hannover-Braunschweig site at the Helmholtz Centre for Infection Research (HZI), leading cutting-edge research in novel anti-infective development. His work focuses on identifying and optimizing antibacterial and antiviral agents through advanced screening platforms and rational design approaches within the German Center for Infection Research (DZIF) framework. His research spans antibacterial discovery against WHO priority pathogens like carbapenem-resistant Pseudomonas aeruginosa (PAFAP project), antiviral development for pandemic preparedness (Nucleoside Booster Project), and host-pathogen interaction studies in cirrhotic patients (TIPINF project). Key methodologies include high-throughput compound screening, natural product exploration, and rational molecular design to overcome resistance mechanisms while minimizing toxicity. Analysis of his 2024-2025 publications reveals strong emphasis on novel antibiotic scaffolds (cystobactamids, terephthalic acids), resistance-breaking strategies (Trojan horse siderophores, mutant enzyme targeting), and toxicity mitigation (colistin prodrugs). The work consistently addresses WHO priority pathogens through diverse approaches including virulence inhibition, redox disruption, and targeted delivery systems. No scientific awards were explicitly mentioned in the source material. Details regarding student advising or specific grant funding were not provided, though his leadership in multi-institutional DZIF projects implies significant collaborative funding. His research group operates within HZI's Antibiotics screening and hit generation working group, leveraging EU OPENSCREEN infrastructure and collaborating across German academic medical centers including Hannover Medical School and TU Braunschweig.

• Mitochondrial Genetics
• mtDNA disease
• Genetic counseling
• +4 more

Professor Joanna Poulton is a Professor of Mitochondrial Genetics at the Nuffield Department of Women's and Reproductive Health (NDWRH) at the University of Oxford. She leads research on mitochondrial DNA diseases and their implications for reproductive medicine and genetic counseling. Her research focuses on three main areas: transmission and recurrence risks in mtDNA disease, diseases of mtDNA maintenance, and mtDNA variants in common multi-factorial diseases. Professor Poulton has developed the current international consensus for reproductive options in mitochondrial disease based on a workshop funded by the European Neuromuscular Centre. Her work on the mtDNA '16189 variant' has demonstrated its role as a risk factor for low birth weight to placental ratio and type 2 diabetes. Analysis of her recent publications reveals a strong focus on mitochondrial disease diagnostics, reproductive options for affected families, and therapeutic approaches for mitochondrial disorders. Her work bridges basic science with clinical applications, particularly in genetic counseling and preimplantation genetic diagnosis. Her scientific achievements include numerous prestigious awards: Royal Society University Research Fellowship (1996) Wellcome Senior Research Fellowship in Clinical Science (1991) Ronnie MacKeith prize from the British Paediatric Neurological Association (1992) RCP award (2013) FRCPCH (1997) Professor Poulton currently supervises doctoral students including Yosuke Matsumiya and Hussam Rostom. Her research is funded by organizations including the Lily Foundation and New Life. She collaborates with researchers globally, including Dr. Rachel Cox at Uniformed Services University in Bethesda, Prof. Suzannah Williams at NDWRH, and researchers at institutions in Bergen, Vienna, Sheffield, Cardiff, Sydney, Newcastle, and UCL. She leads a research group focused on mitochondrial genetics within the NDWRH, working closely with technician Sara Maxwell and collaborating with numerous international researchers in the field of mitochondrial medicine.